Product Image

Contributor Information

  • Name Anne-Marie Mes-Masson and Diane Provencher
  • Institute Centre Hospitalier de L’université de Montréal
  • Primary citation Ouellet et al. 2008. BMC Cancer. (8):152. PMID: 18507860

Tool Details

  • Tool name: TOV-1946 cell line
  • Alternate names: TOV-1946
  • Tool type: Cell Lines
  • Organism: Human
  • Donor: Grade 3 – Stage IIIC; Mutations: TP53 Exon 8; Pre-treatment
  • Tissue: Derived from poorly differentiated serous solid tumors
  • Gender: Female
  • Cancer type: Gynaecologic cancer
  • Morphology: Able to form loose aggregate of cells. Expressed Krt7
  • Growth properties: Adherent
  • CRISPR: No
  • Receptors of note: No
  • Description: Epithelial ovarian cancer cell line derived from poorly differentiated serous solid tumors. Cell line was derived from solid tumor of chemotherapy naive patient who presented poorly differentiated (grade 3) serous papillary cystadenocarcinoma at stage IIC
  • Research area: Cancer
  • Production details: Established using the Scrape method where tumor tissue was scraped into a 100mm plate with complete OSE medium and maintained for 40 days with medium replaced weekly. After 40 days, 80% confluence was attained and cells were divided intwo 2 petri dishes and further divided in a proportion of 2:3 once a week for the first 15 passages and 1:2 twice a week until passage 70. Subsequently, cells were divded in a proportion of 1:5 twice a week.
  • Additional notes: Patient 1946 had no known familial history of cancer and passed from post-operative complications

  • For Research Use Only

Target Details

Application Details

Handling

  • Growth medium: OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin
  • Atmosphere: Hypoxic condition of 5%O2 and 5%CO2
  • Cultured in antibiotics?: Amphotericin B and Gentamicin

Documentation

Related Tools

Product Image

Human uveal melanoma C918 cell line

#160513
Product Image

C6.1 cell line

#161797
Product Image

A549p0#1a Cell Line

#160508

References

  • •  Sauriol et al. 2023. Sci Rep. 27
  • •  13(1):3334. PMID: 36849518 Sevinyan et al. 2022. Cancers (Basel). 16
  • •  14(22):5628. PMID: 36428724 Brodeur et al. 2021. Sci Rep. 14
  • •  11(1):18183. PMID: 34521878 Communal et al. 2021. Int J Mol Sci. 18
  • •  22(10):5325. PMID: 34070214 Patra et al. 2020 PLoS One. 31
  • •  15(12):e0244549. PMID: 33382759